Documentation of published clinical trials and ... - Institut Hiscia

Survival Breast Cancer 5.2.6
Grossarth-Maticek R., Kiene H., Baumgartner S.M., Ziegler R. (2001) Use of Iscador, an extract of
European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and
randomized matched-pair studies nested within a cohort study. Alternative Therapies 7 (3), 57–78.
Study design
Design Prospective, epidemiological long-term study, matched-pair-technique.
Patients Within a collective of breast cancer patients, patients who received
treatment with Iscador were matched with patients who did not receive
treatment with Iscador. 120 pairs could be found after following the strict
criteria required for matching.
Treatment Iscador s.c., individual dosage.
Length of study 1973–1998.
Measurement Survival.
Most important results
The patients treated with Iscador lived, on average, significantly longer than the controls. Breast
cancer without metastases (29 pairs): Iscador 6.08 years vs. control 4.44 years (p = 0.0127);
with metastases in the axilla (38 pairs): Iscador 3.86 years vs. control 2.97 years (p = 0.0002);
with distant metastases (53 pairs): Iscador 3.42 years vs. control 2.38 years (p = 0.00003).
For further results see 3.5, 5.2.5, 5.3.1.2, 5.3.3.3, 5.4.5.
[%] Survivors
100
50
0
0 4 8
Years
12 16 20
© Verein für Krebsforschung, CH-4144 Arlesheim
with Iscador
without Iscador
Fig. 1: Survival of breast cancer patients without metastases over the course of
18 years with an Iscador therapy (n = 29) and without an Iscador therapy (n =
29) (graph according to Grossarth-Maticek et al. 2001).